Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

NCT07383818 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

111

Enrollment

OTHER

Sponsor class

Conditions

HR Positive/HER2 Low Breast Cancer

Interventions

DRUG: Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab
DRUG: Neoadjuvant Chemotherapy in Combination with Toripalimab
DRUG: Neoadjuvant Chemotherapy

Sponsor

First Affiliated Hospital of Zhejiang University